Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia

Brain Research

Volumn 1340, Issue , 2010, Pages 70-80

  Kasahara, Yukiko ^a   Taguchi, Akihiko ^a   Uno, Hisakazu ^a   Nakano, Akiko ^b   Nakagomi, Takayuki ^b   Hirose, Haruka ^a   Stern, David M ^c   Matsuyama, Tomohiro ^b  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c Dean's Office   (United States)

Author keywords

Angiotensin II type1 receptor blocker; Anti inflammation; Ischemia reperfusion cerebral injury; Neuroprotection; PPAR agonist activity

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ANGIOTENSIN 1 RECEPTOR; TELMISARTAN; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN SIZE; DRUG EFFECT; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; STROKE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BRAIN ISCHEMIA; CEREBRAL INFARCTION; DISEASE MODELS, ANIMAL; GLIOSIS; INFLAMMATION MEDIATORS; MALE; MICE; MICE, SCID; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PPAR GAMMA; RECEPTOR, ANGIOTENSIN, TYPE 1; REPERFUSION INJURY;

MURINAE; MUS;

EID: 77953120379     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.03.101     Document Type: Article

References (42)

1. Araki K., Masaki T., Katsuragi I., Tanaka K., Kakuma T., and Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48 (2006) 51-57
2. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., and Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
3. Berl T., Hunsicker L.G., Lewis J.B., Pfeffer M.A., Porush J.G., Rouleau J.L., Drury P.L., Esmatjes E., Hricik D., Pohl M., Raz I., Vanhille P., Wiegmann T.B., Wolfe B.M., Locatelli F., Goldhaber S.Z., and Lewis E.J. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J. Am. Soc. Nephrol. 16 (2005) 2170-2179
4. Calvo C., Hermida R.C., Ayala D.E., and Ruilope L.M. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J. Hypertens. 22 (2004) 837-846
5. del Zoppo G.J., Schmid-Schonbein G.W., Mori E., Copeland B.R., and Chang C.M. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 22 (1991) 1276-1283
6. Forder J.P., Munzenmaier D.H., and Greene A.S. Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H1989-H1996
7. Hamai M., Iwai M., Ide A., Tomochika H., Tomono Y., Mogi M., and Horiuchi M. Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress. Neuropharmacology 51 (2006) 822-828
8. Han F., Shirasaki Y., and Fukunaga K. Microsphere embolism-induced endothelial nitric oxide synthase expression mediates disruption of the blood-brain barrier in rat brain. J. Neurochem. 99 (2006) 97-106
9. Hata R., Mies G., Wiessner C., Fritze K., Hesselbarth D., Brinker G., and Hossmann K.A. A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J. Cereb. Blood Flow Metab. 18 (1998) 367-375
10. Iadecola C., and Alexander M. Cerebral ischemia and inflammation. Curr. Opin. Neurol. 14 (2001) 89-94
11. Iwai M., Liu H.W., Chen R., Ide A., Okamoto S., Hata R., Sakanaka M., Shiuchi T., and Horiuchi M. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 110 (2004) 843-848
12. Iwai M., Inaba S., Tomono Y., Kanno H., Iwanami J., Mogi M., and Horiuchi M. Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. Hypertens. Res. 31 (2008) 161-168
13. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., Hua T., Laragh J., McInnes G.T., Mitchell L., Plat F., Schork A., Smith B., and Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
14. Kagota S., Tada Y., Kubota Y., Nejime N., Yamaguchi Y., Nakamura K., Kunitomo M., and Shinozuka K. Peroxynitrite is involved in the dysfunction of vasorelaxation in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats. J. Cardiovasc. Pharmacol. 50 (2007) 677-685
15. Kaminski A., Pohl C.B., Sponholz C., Ma N., Stamm C., Vollmar B., and Steinhoff G. Up-regulation of endothelial nitric oxide synthase inhibits pulmonary leukocyte migration following lung ischemia-reperfusion in mice. Am. J. Pathol. 164 (2004) 2241-2249
16. Kant S., Schumacher S., Singh M.K., Kispert A., Kotlyarov A., and Gaestel M. Characterization of the atypical MAPK ERK4 and its activation of the MAPK-activated protein kinase MK5. J. Biol. Chem. 281 (2006) 35511-35519
17. Kozak W., Kozak A., Johnson M.H., Elewa H.F., and Fagan S.C. Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. J. Pharmacol. Exp. Ther. 326 (2008) 773-782
18. Li J., Wu F., Zhang H., Fu F., Ji L., Dong L., Li Q., Liu W., Zhang Y., Lv A., Wang H., Ren J., and Gao F. Insulin inhibits leukocyte-endothelium adherence via an Akt-NO-dependent mechanism in myocardial ischemia/reperfusion. J. Mol. Cell. Cardiol. 47 (2009) 512-519
19. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., and Zanchetti A. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens. 22 (2004) 1605-1612
20. Luo Y., Yin W., Signore A.P., Zhang F., Hong Z., Wang S., Graham S.H., and Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J. Neurochem. 97 (2006) 435-448
21. Mabuchi T., Kitagawa K., Ohtsuki T., Kuwabara K., Yagita Y., Yanagihara T., Hori M., and Matsumoto M. Contribution of microglia/macrophages to expansion of infarction and response of oligodendrocytes after focal cerebral ischemia in rats. Stroke 31 (2000) 1735-1743
22. Matsushita K., Matsuyama T., Nishimura H., Takaoka T., Kuwabara K., Tsukamoto Y., Sugita M., and Ogawa S. Marked, sustained expression of a novel 150-kDa oxygen-regulated stress protein, in severely ischemic mouse neurons. Brain Res. Mol. Brain Res. 60 (1998) 98-106
23. Mochizuki S., Dahlof B., Shimizu M., Ikewaki K., Yoshikawa M., Taniguchi I., Ohta M., Yamada T., Ogawa K., Kanae K., Kawai M., Seki S., Okazaki F., Taniguchi M., Yoshida S., and Tajima N. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369 (2007) 1431-1439
24. Mori Y., Itoh Y., and Tajima N. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am. J. Hypertens. 20 (2007) 431-436
25. Nagai N., Oike Y., Izumi-Nagai K., Urano T., Kubota Y., Noda K., Ozawa Y., Inoue M., Tsubota K., Suda T., and Ishida S. Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2252-2259
26. Nakashima M.N., Ajiki K., Nakashima K., and Takahashi M. Possible role of nitric oxide in anxiety following transient cerebral ischemia in mice. J. Pharmacol. Sci. 91 (2003) 47-52
27. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 358 (2001) 1033-1041
28. Saavedra J.M., Benicky J., and Zhou J. Mechanisms of the anti-ischemic effect of angiotensin II AT(1) receptor antagonists in the brain. Cell. Mol. Neurobiol. 26 (2006) 1099-1111
29. Sasaki N., Yamashita T., Takaya T., Shinohara M., Shiraki R., Takeda M., Emoto N., Fukatsu A., Hayashi T., Ikemoto K., Nomura T., Yokoyama M., Hirata K., and Kawashima S. Augmentation of vascular remodeling by uncoupled endothelial nitric oxide synthase in a mouse model of diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1068-1076
30. Sundararajan S., Gamboa J.L., Victor N.A., Wanderi E.W., Lust W.D., and Landreth G.E. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130 (2005) 685-696
31. Suzuki H., and Kanno Y. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens. Res. 28 (2005) 307-314
32. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M.A., Kislinger T., Ingram M., Lu A., Tanaka H., Hori O., Ogawa S., Stern D.M., and Schmidt A.M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405 (2000) 354-360
33. Taguchi A., Soma T., Tanaka H., Kanda T., Nishimura H., Yoshikawa H., Tsukamoto Y., Iso H., Fujimori Y., Stern D.M., Naritomi H., and Matsuyama T. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J. Clin. Invest. 114 (2004) 330-338
34. Takaya T., Kawashima S., Shinohara M., Yamashita T., Toh R., Sasaki N., Inoue N., Hirata K., and Yokoyama M. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 186 (2006) 402-410
35. Takizawa S., Fukuyama N., Hirabayashi H., Nakazawa H., and Shinohara Y. Reperfusion enhances nitrotyrosine formation in rat focal cerebral ischemia. J. Stroke Cerebrovasc. Dis. 12 (2003) 196-200
36. Tamatani M., Matsuyama T., Yamaguchi A., Mitsuda N., Tsukamoto Y., Taniguchi M., Che Y.H., Ozawa K., Hori O., Nishimura H., Yamashita A., Okabe M., Yanagi H., Stern D.M., Ogawa S., and Tohyama M. ORP150 protects against hypoxia/ischemia-induced neuronal death. Nat. Med. 7 (2001) 317-323
37. Teo K., Yusuf S., Sleight P., Anderson C., Mookadam F., Ramos B., Hilbrich L., Pogue J., and Schumacher H. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am. Heart J. 148 (2004) 52-61
38. Tureyen K., Kapadia R., Bowen K.K., Satriotomo I., Liang J., Feinstein D.L., and Vemuganti R. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J. Neurochem. 101 (2007) 41-56
39. Wenzel P., Schulz E., Oelze M., Muller J., Schuhmacher S., Alhamdani M.S., Debrezion J., Hortmann M., Reifenberg K., Fleming I., Munzel T., and Daiber A. AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic. Biol. Med. 45 (2008) 619-626
40. Woollard K.J. Soluble bio-markers in vascular disease: much more than gauges of disease?. Clin. Exp. Pharmacol. Physiol. 32 (2005) 233-240
41. Wu L., Iwai M., Nakagami H., Li Z., Chen R., Suzuki J., Akishita M., de Gasparo M., and Horiuchi M. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 104 (2001) 2716-2721
42. Yusuf S., Diener H.C., Sacco R.L., Cotton D., Ounpuu S., Lawton W.A., Palesch Y., Martin R.H., Albers G.W., Bath P., Bornstein N., Chan B.P., Chen S.T., Cunha L., Dahlof B., De Keyser J., Donnan G.A., Estol C., Gorelick P., Gu V., Hermansson K., Hilbrich L., Kaste M., Lu C., Machnig T., Pais P., Roberts R., Skvortsova V., Teal P., Toni D., VanderMaelen C., Voigt T., Weber M., and Yoon B.W. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med. 359 (2008) 1225-1237